Abstract
You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Non-neurogenic Voiding Dysfunction II1 Apr 2018MP79-13 NOCTURNAL ANTIDIURESIS AFTER ADMINISTRATION OF IMIDAFENACIN IS INDUCED BY CONCENTRATION OF URINE OSMOLALITY Mamoru Hashimoto, Nobutaka Shimizu, Tomoki Takahashi, Koichi Sugimoto, Takafumi Minami, Hirotsugu Uemura, and Akihide Hirayama Mamoru HashimotoMamoru Hashimoto More articles by this author , Nobutaka ShimizuNobutaka Shimizu More articles by this author , Tomoki TakahashiTomoki Takahashi More articles by this author , Koichi SugimotoKoichi Sugimoto More articles by this author , Takafumi MinamiTakafumi Minami More articles by this author , Hirotsugu UemuraHirotsugu Uemura More articles by this author , and Akihide HirayamaAkihide Hirayama More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2681AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Imidafenacin is one of the anti-cholinergic drugs with high affinity to muscarinic type 3 receptor used for alleviating OAB symptoms. Recently, Yamazaki T [1] published data of imidafenacin with inhibitory effects on antidiuretic hormone (ADH) related pathway. We hypothesized that imidafenacin-induced decrease of urine volume at night might be derived from concentration of urine osmolality (Uosm) as a result of inhibiting ADH related pathway (Figure modified from [2] indicates possible mechanism of imidafenacin inhibiting that pathway). This is the first study to evaluate the effectiveness of imidafenacin on Uosm in clinical practice. METHODS A total of 43 OAB patients who had never been administered anti-cholinergic agents were entered in the study. The numbers of male and female patients were 25 and 18, respectively. We examined Uosm, urinary Na/Cre ratio at first void in the morning, nocturnal polyuria index (Npi) based on frequency volume charts, International Prostate Symptom Score (IPSS), over active bladder symptom score (OABSS), maximum urinary flow (Qmax) and residual urine (RU) every four weeks until the 8 weeks visit after administration of imidafenacin. We also classified the patients into two groups according to whether Uosm decreased (Group A) or not (Group B) at 8 weeks visit compared to the baseline. RESULTS Following the administration of imidafenacin, IPSS and OABSS improved significantly in all 43 patients. Npi decreased significantly, and Uosm, urinary Na/Cre ratio, Qmax and RU did not change at 8 weeks visit. The number of patients in Groups A and B was 17 and 18, respectively. Npi decreased significantly only in Group A [Table], which suggested that imidafenacin reduced Npi due to the concentration of Uosm. CONCLUSIONS The beneficial effects of nocturnal antidiuresis after administration of imidafenacin is attributable to the concentration of Uosm. 1. Eur J Pharmacol. 2016 Nov 15;791:72-77. 2. Adv Physiol Educ. 2009 Dec;33(4):270-4. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1085-e1086 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Mamoru Hashimoto More articles by this author Nobutaka Shimizu More articles by this author Tomoki Takahashi More articles by this author Koichi Sugimoto More articles by this author Takafumi Minami More articles by this author Hirotsugu Uemura More articles by this author Akihide Hirayama More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.